In section Market Quotes

Merck Stops Development of Blood Cancer Drug Nemtabrutinib

Merck is ending clinical development of nemtabrutinib, an experimental treatment for chronic lymphocytic leukemia, small lymphocytic leukemia and other blood cancers. The company said a review of trial results raised concern that the drug’s benefits might not outweigh its risks.

Merck Stops Development of Blood Cancer Drug Nemtabrutinib

The decision began with one Phase 3 trial, which Merck discontinued after reviewing results. The company later assessed additional data and stopped two other Phase 3 trials of nemtabrutinib.

The drug had been under evaluation for patients with chronic lymphocytic leukemia, small lymphocytic leukemia and other hematologic malignancies. Merck did not provide further details in its announcement.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!